Commercially available, inactivated influenza virus vaccine administered parenterally stimulates high levels of serum antibody and offers protection against influenza A disease, but the resistance induced is incomplete (18, 26) . For this reason, there is interest in intranasally administered, live attenuated influenza A vaccines that stimulate local and systemic immunity and may provide longer-lasting, more complete protection. Live influenza A virus vaccines consisting of attenuated, cold-adapted (ca) reassortant viruses that possess the six internal RNA segments from the ca A/Ann Arbor/6/60 (H2N2) donor virus and both hemagglutinin (HA) and neuraminidase surface glycoproteins of epidemic wild-type virus are promising (2, 14, 20, 21, 24) .
Data from a previous study indicated that intranasal vaccination of seronegative children with live attenuated ca reassortant HlNl or H3N2 influenza A vaccine efficiently stimulated both systemic and local antibody responses (29) . Local HA-specific antibody responses to live and inactivated influenza A virus vaccines have been incompletely studied in adults. The present study is the first to evaluate the magnitude and duration of the serum and nasal-wash immunoglobulin A (IgA), IgG, and IgM HA antibody responses evoked by vaccination with live or inactivated HlNl or H3N2 influenza A virus in seronegative adult volunteers.
(This study was presented in part at the Second Annual Meeting of the American Society of Virology, Madison, Wis., July 23, 1984 , and at the UCLA Symposia on Molecular and Cellular Biology, Keystone, Colo., April 11, 1985.) MATERIALS AND 
METHODS
Vaccines. The influenza virus vaccines used in this study included two live attenuated, ca reassortant viruses and one commercial, trivalent, inactivated subvirion vaccine. The live attenuated A/Washington/897/80 (H3N2) (antigenically simnilar to A/Bangkok/1/79 virus) and the A/California/10/78 (HlNl) (antigenically similar to A/BrazilV11/78 virus) ca reassortant viruses each possessed the six internal RNA segments derived from the attenuated A/Ann Arbor/6/60 (H2N2) ca donor, whereas the two remaining genes (i.e., those that code for the HA and neuraminidase surface glycoproteins) were derived from their respective wild-type influenza A virus parents. The production and safety testing of these ca reassortant viruses and their evaluation in adults have been described (12, 13, 28 (29, 30) . For detection of IgA, IgG, and IgM HA antibodies, serum and nasal-wash specimens were tested by enzyme-linked immunosorbent assay (ELISA) with specific rabbit anti-human immunoglobulin, as previously described (29) . Briefly, U-bottomed polystyrene microtiter plates (Immulon I; Dynatech Laboratories, Inc., Alexandria, Va.) were used with a ladder of reagents from the solid-to-liquid phase consisting of (i) purified HA, (ii) human serum or nasal wash, (iii) rabbit anti-human IgA, IgG, or IgM, (iv) goat anti-rabbit IgG serum conjugated with alkaline phosphatase, and (v) substrate. The A/California/10/78 (HlNl)-or the A/Bangkok/1/79 (H3N2)-purified HA was used as the homologous antigen in the ELISA. The ELISA titer was expressed as the highest dilution in which the optical density of the antigencontaining well was at least twice the optical density of the respective control well lacking antigen. The ELISA nasalwash IgA, IgM, and IgG HA antibody titers were corrected to an IgA concentration of 10 mg/100 ml, as was done previously (30 tested. Only the data of those vaccine responders whose specimens were collected serially for at least 16 weeks after vaccination were analyzed; these data were obtained from at least 80% of the live virus vaccine responders and from 83% of the inactivated vaccine responders.
The pattern of serum and nasal-wash IgA and IgG HA mean antibody responses in the HlNl vaccinees is shown (Fig. 2) . Live or inactivated virus vaccine induced similar levels of serum IgA and IgG antibodies and nasal IgG antibody. These antibody levels peaked at 2 weeks after vaccination with live virus and 4 weeks after the second vaccination with inactivated virus. In contrast, the live virus vaccine stimulated higher levels of nasal IgA antibody than did inactivated virus vaccine; this antibody peaked at 2 weeks after vaccination. The serum IgG and IgA and nasalwash IgG HA antibodies remained significantly elevated (with a fourfold or greater titer) above prevaccination levels for at least 28 weeks in most of the vaccinees in both immunization groups, whereas the nasal-wash IgA antibody titers remained elevated in about one-half of these vaccinees ( Table 3 ). The levels of serum and nasal-wash IgG antibody remained stable between 2 and 28 weeks after vaccination in both vaccine groups. However, during this interval there was a statistically significant decrease in the levels of both serum and nasal-wash IgA antibodies induced by live HlNl virus vaccination (P < 0.0001) and in the level of serum (but not nasal-wash) IgA antibody induced by inactivated virus vaccination (P < 0.002). This decrease in local IgA antibody titers was not statistically significant because of the small number of specimens tested.
The pattern of serum and nasal-wash antibody responses to live or inactivated virus vaccine in the H3N2 vaccinees is illustrated in Fig. 3 
DISCUSSION
The relative role of specific antibodies in protection against influenza has not been established. However, evidence from studies in animals and humans suggests that both secretory and serum antibodies may be mediators of immunity to influenza infection, disease, or both (1, 4, 15 (14, 31) . However, some live attenuated influenza viruses administered at high doses can induce levels of serum antibodies of the same magnitude as those induced by the homologous wild-type virus. For example, the A/Washington/897/80 (H3N2) and A/California/10/78 (H1N1) ca vaccine viruses, when administered intranasally at doses comparable to those in the present study, stimulated serum antibody levels as high as those induced by experimental infection with wildtype virus (12, 28) .
Previous studies in primed and unprimed children and adults have demonstrated that the levels of antibody in serum decline significantly within 6 to 8 months after parenteral vaccination with subvirion vaccine (9, 11, 22) but not after intranasal vaccination with live attenuated virus or after natural infection (11, 18a, 36 Francis (17) observed that subcutaneous injection of adults with influenza vaccine enhanced the inactivating capacity of their nasal secretions. Others confirmed this finding and identified this substance as neutralizing antibody, mainly polymeric IgA antibody containing secretory component (6, 19, 27, 32, 35) . More recently, IgG and IgM HA-specific antibody responses to live and inactivated influenza vaccines have been measured in nasal-wash specimens (18a, 29, 37) . In studies with seronegative adults, Zahradnik and co-workers (37) detected nasal IgG HA antibody increases by radioimmunoprecipitation assay in one-third of inactivated virus recipients but in only 6% of live virus vaccinees. Johnson (3-5, 7, 8, 29) . In earlier studies (7, 29) nasal and serum IgA HA antibodies in live virus vaccinees was observed, suggesting that these antibodies might be derived from the same source. Brown and colleagues (6) found that IgA HA-specific antibody in nasal-wash specimens after infection with wild-type virus was composed almost entirely of polymeric (11S) secretory IgA. Furthermore, the serum IgA HA antibody from these volunteers contained a higher proportion of J-chain-containing polymeric IgA with respect to monomeric IgA than total serum IgA, suggesting that serum IgA HA-specific antibody induced by live virus vaccination was of mucosal origin. The findings in the present study are consistent with the concept of a mucosally derived serum and with nasal-wash IgA antibodies in live virus vaccinees, i.e., the magnitude of their serum and pasal-wash IgA HIA antibodies were related and there was a concomitant decrease in these antibody populations over 6 months. The origin of nasal antibodies, particularly IgG HA antibody, induced by subcutaneously administered inactivated virus vaccine, is intriguing but cannot be unequivocally identified by our findings. The positive correlation coefficient between postvaccination levels of nasal and serum IgG HA antibodies in our inactivated virus vaccinees suggests that these populations of antibody are derived from the same source. The observation that levels of both serum and nasal-wash IgG HA antibodies remained stable up to 6 months after vaccination while nasal-wash IgA levels declined supports the concept that nasal IgG HA antibody is derived from serum antibody by passive transudation. This possibility requires further study.
Serum IgG influenza antibody has been shown to prevent lethal pneumonia in infected animals and to correlate with resistance to influenza illness in neonates (33, 34) ; however, the role of nasal-wash IgG antibody in protection against influenza has not been defined. A previous study demonstrated a relationship between resistance to influenza infection and specific IgG in nasal secretions (15) . Clearly, the function of inactivated influenza vaccine-induced IgG in nasal secretions should be ivestigated further.
Results of earlier stud-have demonstrated that, in the absence of serum antibodies, local IgA antibody is a major determinant of resistance to infection and illness in volunteers challenged with wild-type virus (13 
